3 Reasons to Sell PEN and 1 Stock to Buy InsteadThe past six months have been a windfall for Penumbra’s shareholders. The company’s stock price has jumped 55.5%, setting a new 52-week high of $355.93 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)BALA CYNWYD, Pa., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
3 High-Flying Stocks That Fall ShortExpensive stocks often command premium valuations because the market thinks their business models are exceptional.
However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.
"Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting LandscapeAs 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a strategic pivot toward high-growth technology. Morgan Stanley (
NYSE: MS) recently released a bullish outlook for the year, projecting a
Why Penumbra (PEN) Stock Is Trading Up TodayShares of medical device company Penumbra (
NYSE:PEN)
jumped 12.1% in the afternoon session after the company agreed to be acquired by Boston Scientific in a deal valued at approximately $14.5 billion.
The Thrombectomy Titan: Boston Scientific Shakes MedTech with $14.5 Billion Penumbra AcquisitionMARLBOROUGH, MA – In a move that has sent shockwaves through the medical device sector, Boston Scientific Corporation (
NYSE:BSX) announced today, January 15, 2026, a definitive agreement to acquire Penumbra, Inc. (
NYSE:PEN) for approximately $14.5 billion. The blockbuster deal, the largest in the industry since the early 2020s,
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), Clearwater Analytics Holdings, Inc. (NYSE - CWAN)BALA CYNWYD, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
PEN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Penumbra, Inc. is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Penumbra, Inc. (
NYSE: PEN) to Boston Scientific Corporation for $374.00 in cash or 3.8721 shares of Boston Scientific common stock is fair to Penumbra shareholders.
1 Healthcare Stock to Keep an Eye On and 2 We IgnoreFrom novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns
as healthcare stocks have gained 18.7% over the past six months while the S&P 500 was up 11.1%.
3 Cash-Heavy Stocks We Steer Clear OfA cash-heavy balance sheet is often a sign of strength, but not always.
Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
3 Mid-Cap Stocks with Open QuestionsMid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
3 Inflated Stocks We’re Skeptical OfThe stocks featured in this article are seeing some big returns.
Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q3 In Review: Penumbra (NYSE:PEN) Vs PeersLooking back on medical devices & supplies - cardiology, neurology, vascular stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Penumbra (
NYSE:PEN) and its peers.
Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To KnowA number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.
1 Cash-Heavy Stock to Consider Right Now and 2 Facing HeadwindsA cash-heavy balance sheet is often a sign of strength, but not always.
Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
3 Cash-Producing Stocks We Steer Clear OfA company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
2 Healthcare Stocks to Keep an Eye On and 1 We Find RiskyHealthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s 9.8% return has trailed the S&P 500 by 7.3 percentage points.
